License agreement between CONICET and GSK for an anti-MICA monoclonal antibody
CONICET and GSK announced a license agreement for a preclinical anti-MICA monoclonal antibody as a potential cancer treatment. In preclinical models, this technology delayed the growth of tumors by acting directly on the MICA proteins that are expressed on the surface of tumor cells. The license agreement contemplates an initial payment to CONICET...